| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 股票交易风险提示性公告 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续2个交 易日（2026年1月5日、1月6日）收盘价格涨停，公司股价近期存在大幅波动的风 险，敬请广大投资者审慎理性决策，注意二级市场交易风险。 公司倡导价值投资并将会专注于主业的发展，公司敬请广大投资者注意 二级市场交易风险，理性决策、审慎投资。 一、二级市场交易风险 公司股票于2026年1月5日、1月6日连续2个交易日收盘价格涨停，公司股价 近期存在大幅波动的风险，敬请广大投资者审慎理性决策，注意二级市场交易风 险，理性决策，审慎投资。 二、生产经营风险 公司目前日常生产经营活动正常，主营业务未发生重大变化。 公司于 2025 年 10 月 30 日披露的《2025 年第三季度报告》，2025 年第三季 度归属于上市公司股东未经审计的净利润为-8,724.41 万元,较上年同期减少 3,121.90 万元，以上 ...

塞力斯医疗科技集团股份有限公司 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 关于"塞力转债"交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： "塞力转债"于2025年12月31日、2026年1月5日、2026年1月6日连续3 个交易日收盘价格涨幅偏离值累计超过30%，根据《上海证券交易所可转换公司 债券交易实施细则》的相关规定，属于可转债交易异常波动情况。 截至2026年1月6日收盘，"塞力转债"收盘价格为286.301元/张，相对 于票面价格溢价186.30%，转股溢价率38.14%。敬请广大投资者注意当前估值风 险，理性投资。 经公司自查，并向控股股东赛海（上海）健康科技有限公司及实际控制 人温伟先生发函核实，截至本公告披露日，控股股东及实际控制人不存在应披露 而未披露的重大信息。 风险提示详见本公告"四、相关风险提示"，公司倡导价值投资并专注 于主 ...

证券之星消息，1月6日互联网医疗板块较上一交易日上涨1.5%，塞力医疗领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。互联网医疗板块个股涨跌见下表： 从资金流向上来看，当日互联网医疗板块主力资金净流出17.51亿元，游资资金净流出3.81亿元，散户资 金净流入21.33亿元。互联网医疗板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗信息化板块主力资金净流出10.96亿元，游资资金净流出2.72亿元，散户资 金净流入13.68亿元。医疗信息化板块个股资金流向见下表： 证券之星消息，1月6日医疗信息化板块较上一交易日上涨1.33%，塞力医疗领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗信息化板块个股涨跌见下表： ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

据交易所数据显示， 塞力医疗连续两个交易日涨停，晋级2连板。该股今日于9时25分封涨停，成交额 1.36亿元，换手率2.60%。金融界App AI线索挖掘：近期 脑机接口概念板块延续涨势，相关领域被推动 成为新的经济增长点，同时国际头部企业宣布2026年将对脑机接口设备进行大规模生产，市场对该领域 的关注度持续提升。塞力医疗作为脑机接口概念相关个股，受板块整体热度影响。 风险提示：连板股 波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生成，内容不构成投资 建议。） ...

Core Viewpoint - The brain-computer interface sector continues to experience significant growth, with multiple companies achieving consecutive trading gains. Group 1: Company Performance - Sanbo Brain Science (301293), Meihao Medical (301363), Innovation Medical (002173), Pulite (002324), Saily Medical (603716), Yanshan Technology (002195), and Yingqu Technology (002925) have all recorded two consecutive trading limit-ups [1]

| | | 塞力斯医疗科技集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有 23,182 万元"塞力 转债"转为公司普通股，累计转股股数为 19,288,938 股，占"塞力转债"转股 前公司总股本的比例为 9.4084%。 一、塞力转债发行上市概况 （一）可转换公司债券发行情况 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 54,331万元的可转换公司债券于2020年9月15日起在上海证券交易所挂牌交易， 债券 ...

Market Performance - The pharmaceutical commercial sector increased by 1.77% compared to the previous trading day, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Individual Stock Performance - Jia Shitang (002462) closed at 15.80, up 10.03% with a trading volume of 224,800 shares [1] - Saily Medical (603716) closed at 22.61, up 10.02% with a trading volume of 133,500 shares [1] - Baiyang Pharmaceutical (301015) closed at 25.23, up 6.91% with a trading volume of 83,200 shares [1] - Other notable performers include Dajia Weikang (301126) up 6.51%, and Run Da Medical (603108) up 5.82% [1] Capital Flow Analysis - The pharmaceutical commercial sector saw a net inflow of 231 million yuan from institutional investors, while retail investors contributed a net inflow of 71.88 million yuan [2] - However, there was a net outflow of 303 million yuan from speculative funds [2] Detailed Capital Flow for Key Stocks - Saily Medical (603716) had a net inflow of 1.59 billion yuan from institutional investors, but a net outflow of 71.84 million yuan from speculative funds [3] - Jia Shitang (002462) experienced a net inflow of 86.98 million yuan from institutional investors, with a net outflow of 45.96 million yuan from speculative funds [3] - Hua Ren Health (301408) had a net inflow of 45.75 million yuan from institutional investors, but a significant net outflow of 65.32 million yuan from retail investors [3]

Group 1 - The cell immunotherapy concept increased by 4.73%, ranking 7th among concept sectors, with 56 stocks rising, including Guanhao Biological reaching a 20% limit up [1] - Notable gainers in the sector include International Medicine, Saily Medical, and Zhaoyan New Drug, all hitting the limit up, while stocks like Saifutian and *ST Biology experienced declines [1][2] - The cell immunotherapy sector saw a net inflow of 1.058 billion yuan, with 38 stocks receiving net inflows, and Zhaoyan New Drug leading with a net inflow of 232 million yuan [2][3] Group 2 - The top stocks by net inflow ratio include Saily Medical at 57.96%, International Medicine at 41.60%, and Zhaoyan New Drug at 22.45% [3] - The trading performance of key stocks shows Zhaoyan New Drug and Saily Medical both achieving over 10% gains, while Guanhao Biological reached a 20% increase [3][4] - Other notable performers include Bibeite and Yuekang Pharmaceutical, with increases of 11.84% and 10.13% respectively [1][5]